Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killing
Targeting immune checkpoints such as programmed cell death protein 1 (PD-1) and programmed death ligand-1 (PD-L1) have been approved for treating melanoma, gastric cancer (GC) and bladder cancer with clinical benefit. Nevertheless, many patients failed to respond to anti-PD-1/PD-L1 treatment, so it...
Saved in:
Main Authors: | Zhiru Wang (Author), Wenting Kang (Author), Ouwen Li (Author), Fengyu Qi (Author), Junwei Wang (Author), Yinghua You (Author), Pengxing He (Author), Zhenhe Suo (Author), Yichao Zheng (Author), Hong-Min Liu (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2021-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
USP7: Novel Drug Target in Cancer Therapy
by: Zhiru Wang, et al.
Published: (2019) -
BCG downregulates PD1 and PD-L1 expression in bladder cancer cells co-cultivated with peripheral blood mononuclear cells
by: Katia R. M. Leite, et al.
Published: (2022) -
Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy via diminishing PD-L1 and promoting CD8+ T cell-mediated ferroptosis in castration-resistant prostate cancer
by: Xumin Zhou, et al.
Published: (2022) -
Liraglutide abrogates nephrotoxic effects of chemotherapies
by: Cong Xu, et al.
Published: (2023) -
Constitutive activation of BMP signalling abrogates experimental metastasis of OVCA429 cells via reduced cell adhesion
by: Shepherd Trevor G, et al.
Published: (2010)